In this study, we utilized scRNA-seq profiles of CD8+ T cells in melanoma to derive a cluster of tumor-reactive T cells, and further developed a tumor-reactive signature (TRS) to indicate the tumor reactivity of tumor samples. This evidence concerns the gene CD8A and neoplasm.